The FDA's acceptance of the BLA for Priority Review and the subsequent PDUFA date will be the next key catalysts. Monitor for FDA filing acceptance and any advisory committee meeting announcements. The stock has historically sold off on prior news events, so position sizing should account for binary risk.
Price Chart
Executive Summary
DBV Technologies submitted a Biologics License Application (BLA) to the FDA for the VIASKIN Peanut Patch in children aged 4-7 years, supported by positive Phase 3 VITESSE trial data (654 patients). The company requested Priority Review, and the FDA had previously granted Breakthrough Therapy Designation. This is a major regulatory milestone for a pre-revenue biotech with no approved products, but approval is not guaranteed and the stock has historically declined on prior catalysts.
Key Facts
- BLA submitted to FDA for VIASKIN Peanut Patch in children aged 4-7 years with peanut allergy
- Priority Review requested; FDA previously granted Breakthrough Therapy Designation
- BLA supported by positive results from Phase 3 VITESSE trial (654 children, largest immunotherapy trial for this population)
- Company has no approved products in any country; this is a pivotal regulatory submission
Financial Impact
No financial figures disclosed in the filing; the BLA submission is a binary catalyst with potential to unlock a large market if approved, but no revenue or deal value stated.
Risk Factors
- FDA may not accept the BLA for filing or grant Priority Review as requested
- Clinical data may not support approval; FDA could issue a Complete Response Letter
- Company has no commercial infrastructure or approved products; commercialization risk if approved
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-408052 |
| Document: d118963dex991.htm | 0001193125-26-408052 |
| Document: 0001193125-26-408052-index-headers.html | 0001193125-26-408052 |
| Document: 0001193125-26-408052-index.html | 0001193125-26-408052 |
| Document: 0001193125-26-408052.txt | 0001193125-26-408052 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 26d ago | 8-K | $11.76 $9.77 | ▼ −16.92% | ▼ −18.83% | $9.91 (−15.73%) |
Jul 27, 2026 13w ago | S-3ASR | $13.90 $13.50 | ▲ +2.88% | ▲ +3.95% | $9.91 (+28.71%) |
Jul 6, 2026 15w ago | Press Release | $17.35 $15.92 | ▼ −8.24% | ▼ −8.79% | $9.91 (−42.88%) |
Jun 29, 2026 16w ago | 8-K | $16.40 $15.61 | ▼ −4.82% | ▼ −5.42% | $9.91 (−39.57%) |
Apr 30, 2026 25w ago | Press Release | $19.87 $19.73 | ▼ −0.70% | ▼ −3.05% | $9.91 (−50.13%) |
Mar 26, 2026 30w ago | Press Release | $20.00 $20.36 | ▲ +1.80% | ▼ −2.06% | $9.91 (−50.45%) |
Mar 26, 2026 30w ago | Press Release | $20.00 $20.36 | ▲ +1.80% | ▼ −2.06% | $9.91 (−50.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers